INMOLECULE risk profile
30 Normal where most of the sector sits
Measured 21 October 2026 from MLINA.PA's filed statements. Recomputed nightly.
30 (Normal), driven by Leverage and coverage at 74, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 39 | Normal | Stable | Average daily turnover — $15 |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -60.3 percentage points |
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 74 | Stretched | Easing | Net debt to EBITDA — 50.76x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.